企业QQ
官方微信
简述：
张博士：我们知道最近默沙东新成立了一个BioVentures部门，并开始设计生物仿制药的领域，这是否意味着默沙东的战略
张博士：我们知道最近默沙东新成立了一个BioVentures部门，并开始设计生物仿制药的领域，这是否意味着默沙东的战略开始调整？
Mr. Greg Wiederrecht
Mr. Greg Wiederrecht(Vice President Head, External Scientific Affairs, Worldwide Licensing External Research, Merck Co., Inc.)：Biologic therapeutics are approved for many important medical needs. In 2007, biologics accounted for $94 billion in sales. Follow-on biologics represent a significant market opportunity due to extensive patent expiries through 2017. Merck BioVentures has an opportunity to capitalize on upcoming patent expirations of currently marketed biologic therapeutics. GlycoFi Pichia provides a superior platform for biologics. and experience in follow-on biologics and proprietary technologies applicable to development of novel biologics. The goal of Merck BioVentures is become a global leader in the Follow-on-Biologics business by developing and selling quality, low cost, high POS products against known targets.
The differentiators from current Merck business as following: 1. High POS: informed by original innovator\'s development program; 2. entry into market must occur within defined \"launch window\"; 3. low cost: manufacture and operations essential to compete in Follow On Biologics market. The commonalities with current Merck business as following：1. product needs to have good safety and efficacy profile; 2. high quality products required; 3. Multiple stakeholder involved in purchase/usage decision.